Climb Bio, Inc. Common Stock

Day range

$8.75 – $9.99

Open

$9.88

Prev close

$10.19

Volume

1.28M

Market cap

$585.28M

Shares out

57.44M

P/E

—

P/S

—

P/B

2.44

P/FCF

—

ROE

-24.1%

ROA

-23.4%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsOct 23, 2026

  CLYM116 has been generally well tolerated across all dose levels evaluated with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia. Injection site reactions occurred in 5 of 88 participants across both studies, which were all Grade 1 and resolved without intervention.

• Clinical trial resultsSep 3, 2026

  On September 3, 2026, Climb Bio, Inc. (the "Company") issued a press release and published a corporate presentation announcing positive results from its ongoing Phase 1 trial evaluating CLYM116, an anti-APRIL monoclonal antibody.

• Director departureJul 1, 2026

  On June 29, 2026, Andrew Levin notified the board of directors (the "Board") of Climb Bio, Inc. (the "Company") of his resignation as a member of the Board, effective immediately.

• Underwriting agreementJun 12, 2026

  On June 12, 2026, Climb Bio, Inc., a Delaware corporation (the "Company"), entered into an Open Market Sale Agreement℠ (the "Sales Agreement") with Jefferies LLC, as agent ("Jefferies"), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the "Common Stock"), from time to time through Jefferies... the Company may offer and sell shares of Common Stock having an aggregate offering price of up to $100.0 million under the Sales Agreement (the "Shares").

• Clinical trial resultsJun 11, 2026

  In the 250 mg dose cohort, B-cell levels were depleted by an average of over 90% by Week 4 and mean platelet count increased by 111,000 platelets/µL at Week 24. Durable platelet responses were achieved in four out of six patients in the 250 mg dose cohort, with two out of six patients experiencing platelet levels ≥100 x 103/µL for over 24 weeks.

Days to cover

5.6

Short interest

9.72M

Avg volume

1.72M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
  positiveGlobeNewswire Inc.· Oct 24, 2026
• Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight
  positiveGlobeNewswire Inc.· Apr 6, 2026
• Climb Bio to Present at Upcoming Investor Conferences
  neutralGlobeNewswire Inc.· Feb 5, 2026
• Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  neutralGlobeNewswire Inc.· Nov 25, 2025
• Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
  positiveGlobeNewswire Inc.· Oct 17, 2025